Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 11 | 1 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Liver Fibrosis Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Liver Fibrosis Overview | 15 | 1 |
| Pipeline Products for Liver Fibrosis Comparative Analysis | 16 | 1 |
| Liver Fibrosis Therapeutics under Development by Companies | 17 | 3 |
| Liver Fibrosis Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Liver Fibrosis Pipeline Products Glance | 21 | 2 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Liver Fibrosis Products under Development by Companies | 23 | 4 |
| Liver Fibrosis Products under Investigation by Universities/Institutes | 27 | 1 |
| Liver Fibrosis Companies Involved in Therapeutics Development | 28 | 42 |
| Advinus Therapeutics Ltd | 28 | 1 |
| Akarna Therapeutics Ltd. | 29 | 1 |
| Angion Biomedica Corp. | 30 | 1 |
| Asubio Pharma Co., Ltd. | 31 | 1 |
| aTyr Pharma, Inc. | 32 | 1 |
| Beijing Kawin Technology Share-Holding Co., Ltd. | 33 | 1 |
| BioLineRx, Ltd. | 34 | 1 |
| Bioneer Corporation | 35 | 1 |
| BiOrion Technologies B.V. | 36 | 1 |
| Bird Rock Bio, Inc. | 37 | 1 |
| Bristol-Myers Squibb Company | 38 | 1 |
| Cellmid Limited | 39 | 1 |
| ContraVir Pharmaceuticals, Inc. | 40 | 1 |
| Dicerna Pharmaceuticals, Inc. | 41 | 1 |
| Digna Biotech, S.L. | 42 | 1 |
| Dr. Falk Pharma GmbH | 43 | 1 |
| Dynavax Technologies Corporation | 44 | 1 |
| Evotec AG | 45 | 1 |
| Galectin Therapeutics, Inc. | 46 | 1 |
| Genfit SA | 47 | 1 |
| Gilead Sciences, Inc. | 48 | 1 |
| GNI Group Ltd. | 49 | 1 |
| HEC Pharm Co., Ltd. | 50 | 1 |
| Immuron Limited | 51 | 1 |
| Intercept Pharmaceuticals, Inc. | 52 | 1 |
| INVENT Pharmaceuticals, Inc. | 53 | 1 |
| Isarna Therapeutics GmbH | 54 | 1 |
| KineMed, Inc. | 55 | 1 |
| LG Life Science LTD. | 56 | 1 |
| Nitto Denko Corporation | 57 | 1 |
| Pfizer Inc. | 58 | 1 |
| Pharmaxis Limited | 59 | 1 |
| Promedior, Inc. | 60 | 1 |
| Promethera Biosciences S.A. | 61 | 1 |
| ProMetic Life Sciences Inc. | 62 | 1 |
| Ribomic Inc. | 63 | 1 |
| RXi Pharmaceuticals Corporation | 64 | 1 |
| Silence Therapeutics Plc | 65 | 1 |
| TCM Biotech International Corp | 66 | 1 |
| Vascular Biogenics Ltd. | 67 | 1 |
| Virobay Inc. | 68 | 1 |
| XTuit Pharmaceuticals, Inc. | 69 | 1 |
| Liver Fibrosis Therapeutics Assessment | 70 | 13 |
| Assessment by Monotherapy Products | 70 | 1 |
| Assessment by Combination Products | 71 | 1 |
| Assessment by Target | 72 | 4 |
| Assessment by Mechanism of Action | 76 | 3 |
| Assessment by Route of Administration | 79 | 2 |
| Assessment by Molecule Type | 81 | 2 |
| Drug Profiles | 83 | 101 |
| ANG-3070 Drug Profile | 83 | 1 |
| ANG-3281 Drug Profile | 84 | 1 |
| Antisense RNAi Oligonucleotide for Liver Disease Drug Profile | 85 | 1 |
| Antisense RNAi Oligonucleotide for Liver Diseases Drug Profile | 86 | 1 |
| Antisense RNAi Oligonucleotide for Liver Fibrosis Drug Profile | 87 | 1 |
| Antisense RNAi Oligonucleotide for Liver Fibrosis Drug Profile | 88 | 1 |
| Antisense RNAi Oligonucleotide for Liver Fibrosis Drug Profile | 89 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis Drug Profile | 90 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis Drug Profile | 91 | 1 |
| ASB-14780 Drug Profile | 92 | 1 |
| BL-1210 Drug Profile | 93 | 1 |
| BMS-986171 Drug Profile | 94 | 1 |
| BOT-162 Drug Profile | 95 | 1 |
| BOT-191 Drug Profile | 96 | 1 |
| CAB-102 Drug Profile | 97 | 2 |
| CPI-43132 Drug Profile | 99 | 3 |
| CT-140 Drug Profile | 102 | 1 |
| DB-036 Drug Profile | 103 | 1 |
| Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis Drug Profile | 104 | 1 |
| Drugs for Tissue Fibrosis Drug Profile | 105 | 1 |
| DV-1079 Drug Profile | 106 | 2 |
| F-351 Drug Profile | 108 | 2 |
| Gene Therapy for Liver Fibrosis Drug Profile | 110 | 1 |
| GMCT-01 Drug Profile | 111 | 4 |
| GRMD-02 Drug Profile | 115 | 11 |
| GS-444217 Drug Profile | 126 | 1 |
| HEC-585 Drug Profile | 127 | 1 |
| HepaStem Drug Profile | 128 | 2 |
| IMM-124E Drug Profile | 130 | 3 |
| INT-767 Drug Profile | 133 | 1 |
| INV-240 Drug Profile | 134 | 1 |
| ISTH-0047 Drug Profile | 135 | 2 |
| KW-0 Drug Profile | 137 | 1 |
| KW-012 Drug Profile | 138 | 1 |
| LC-280126 Drug Profile | 139 | 1 |
| melittin Drug Profile | 140 | 1 |
| Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis Drug Profile | 141 | 1 |
| MOR-8457 Drug Profile | 142 | 1 |
| MRI-1867 Drug Profile | 143 | 1 |
| ND-L02s0201 Drug Profile | 144 | 2 |
| norursodeoxycholic acid Drug Profile | 146 | 1 |
| noscapine Drug Profile | 147 | 1 |
| PBI-4050 Drug Profile | 148 | 5 |
| PRM-151 Drug Profile | 153 | 5 |
| Proteins for Liver Fibrosis Drug Profile | 158 | 1 |
| PXS-4820 Drug Profile | 159 | 1 |
| PXS-5033A Drug Profile | 160 | 1 |
| RBM-006 Drug Profile | 161 | 1 |
| Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation Drug Profile | 162 | 1 |
| RXI-209 Drug Profile | 163 | 1 |
| RYI-018 Drug Profile | 164 | 1 |
| selonsertib Drug Profile | 165 | 1 |
| selonsertib + simtuzumab Drug Profile | 166 | 1 |
| Small Molecule for Liver Fibrosis Drug Profile | 167 | 1 |
| Small Molecule for Liver Fibrosis Drug Profile | 168 | 1 |
| Small Molecule to Agonize FXR for NASH and Liver Fibrosis Drug Profile | 169 | 1 |
| Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile | 170 | 1 |
| Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis Drug Profile | 171 | 1 |
| Small Molecules for Hepatic Fibrosis Drug Profile | 172 | 1 |
| Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 173 | 1 |
| Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis Drug Profile | 174 | 1 |
| Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis Drug Profile | 175 | 1 |
| TCM-808FB Drug Profile | 176 | 1 |
| TGFTX-4 Drug Profile | 177 | 1 |
| VB-201 Drug Profile | 178 | 3 |
| VB-703 Drug Profile | 181 | 1 |
| VBY-376 Drug Profile | 182 | 1 |
| VBY-825 Drug Profile | 183 | 1 |
| Liver Fibrosis Dormant Projects | 184 | 4 |
| Liver Fibrosis Discontinued Products | 188 | 1 |
| Liver Fibrosis Product Development Milestones | 189 | 9 |
| Featured News &Press Releases | 189 | 1 |
| Aug 01, 2016: Supplemental Toxicology Study to be Undertaken Pursuant to the Investigational New Drug Application with the US FDA for F351/Hydronidone | 189 | 1 |
| Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis | 189 | 1 |
| May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis | 189 | 1 |
| May 06, 2016: Additional Data Requested by US FDA for the Investigational New Drug (IND) Application for F351/Hydronidone | 190 | 1 |
| Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016 | 190 | 1 |
| Apr 14, 2016: ProMetic confirms PBI-4050 Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells | 191 | 1 |
| Mar 11, 2016: GNI Group Files Investigational New Drug with U.S. FDA for Clinical Trials for F351/Hydronidone in the Treatment of Liver Fibrosis | 192 | 1 |
| Nov 30, 2015: Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist | 192 | 1 |
| Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases | 193 | 1 |
| May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam | 193 | 1 |
| Mar 12, 2015: Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA | 194 | 1 |
| Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease | 195 | 1 |
| Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter | 195 | 1 |
| Apr 10, 2014: ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver Fibrosis and Liver Cancer | 196 | 1 |
| Jan 21, 2014: Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis | 197 | 1 |
| Appendix | 198 | 2 |
| Methodology | 198 | 1 |
| Coverage | 198 | 1 |
| Secondary Research | 198 | 1 |
| Primary Research | 198 | 1 |
| Expert Panel Validation | 198 | 1 |
| Contact Us | 198 | 1 |
| Disclaimer | 199 | 1 |